Chris Murphy

This committee should study these trends and discuss what we can do for workers and small business owners to keep the American Dream in reach for all families.

Workers can only exercise their basic rights, rights that are guaranteed under the Constitution and the National Labor Relations Act, when all of the employers who have a say in their working conditions are at the table.

This decision does not change the relationship between a local business owner and her employees.

When workers want to join together with their coworkers, they are not looking for special treatment.

I believe we need to help our workers and grow our economy from the middle out, not from the top down.

I think I share some of the sentiments that Senator Cardin has expressed regarding what is a hard-fought and hard-won compromise, but a compromise first, second, and third.

These agreements that have been negotiated under this administration have done more to open the door toward these types of activities than I ever would have anticipated

Thank you, Mr. Chairman.

These reductions will result in significant savings to the healthcare system and patients as the biosimilar market matures.

If we get a whole rash of State laws that erect barriers it doesn't really matter what education you do if the law prevents the usage of these biosimilars.

We can do all of this work on trying to make sure that we approve biosimilars, but if they're not actually getting prescribed, if we aren't giving FDA the resources to make the case that they should be prescribed, we're going to be…

If we are successful in getting this pathway to biosimilars moving then my fear is with a product sitting on the market that could cost 30 percent less we are going to be behind this avalanche of pharmaceutical advertising that will keep…

I know this is an issue that doesn't necessarily fit natural to Congress to be funding physician and provider education, but we're talking about next year reports suggesting that 8 of the top 10 drugs on the market are going to be…

It took us a long time to educate both providers and patients about chemical generics.

We talked about the certainty that the industry needs to start populating the field with more biosimilars.

I hope that we can talk about that today.

This increased cost is born by our healthcare system as a whole, but more specifically by patients as more and more insurance companies place higher cost sharing burdens on biologics.

Biologics have provided major advances in the treatment of cancer, rheumatologic disease, and other conditions.

I did not see it while I was there.

I think that there is a potentially really significantly high cost to the United States compared to what I would suggest is a potentially really low positive reward.

I agree with everything you have said, and I just want to make sure that we have a sober understanding of, amongst those problems, which ones we can solve and which ones we cannot.

I still am not clear whether we are pressing the right levers internally to get the kind of political reconciliation necessary.

I sort of still feel like there is this leftover hubris in which we think that we are the most important player in the region.

It is a sound strategy, but how is it working?

Our effectiveness in combating the ISIL threat cannot be measured solely by the number of sorties flown.